Mark Connors

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3405249/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	35
2	Immunologic Control of HIV-1: What Have We Learned and Can We Induce It?. Current HIV/AIDS Reports, 2021, 18, 211-220.	3.1	7
3	SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn. Annals of Internal Medicine, 2021, 174, 687-690.	3.9	64
4	Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography. Antibodies, 2021, 10, 23.	2.5	2
5	Antigenic Restimulation of Virus-Specific Memory CD8 ⁺ T Cells Requires Days of Lytic Protein Accumulation for Maximal Cytotoxic Capacity. Journal of Virology, 2020, 94, .	3.4	9
6	Prolonged evolution of the memory B cell response induced by a replicating adenovirus-influenza H5 vaccine. Science Immunology, 2019, 4, .	11.9	40
7	Toll-like receptor 7-adapter complex modulates interferon-α production in HIV-stimulated plasmacytoid dendritic cells. PLoS ONE, 2019, 14, e0225806.	2.5	3
8	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight, 2019, 4, .	5.0	6
9	Title is missing!. , 2019, 14, e0225806.		0
10	Title is missing!. , 2019, 14, e0225806.		0
11	Title is missing!. , 2019, 14, e0225806.		0
12	Title is missing!. , 2019, 14, e0225806.		0
13	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports, 2018, 22, 1798-1809.	6.4	52
14	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathogens, 2018, 14, e1006860.	4.7	68
15	Killer cell immunoglobulin–like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. Journal of Clinical Investigation, 2018, 128, 1903-1912.	8.2	52
16	Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity, 2017, 46, 777-791.e10.	14.3	81
17	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. Journal of Virology, 2017, 91, .	3.4	40
18	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science, 2017, 358, 85-90.	12.6	225

MARK CONNORS

#	Article	IF	CITATIONS
19	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. PLoS Pathogens, 2017, 13, e1006074.	4.7	33
20	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. Cell, 2016, 165, 813-826.	28.9	379
21	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology, 2016, 90, 5899-5914.	3.4	62
22	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science, 2016, 352, 828-833.	12.6	310
23	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity, 2016, 45, 1108-1121.	14.3	304
24	Class II-Restricted CD8s: New Lessons Violate Old Paradigms. Immunity, 2016, 45, 712-714.	14.3	4
25	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
26	CD8+ T-cell Cytotoxic Capacity Associated with Human Immunodeficiency Virus-1 Control Can Be Mediated through Various Epitopes and Human Leukocyte Antigen Types. EBioMedicine, 2015, 2, 46-58.	6.1	27
27	Success and failure of the cellular immune response against HIV-1. Nature Immunology, 2015, 16, 563-570.	14.5	88
28	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell, 2015, 161, 470-485.	28.9	226
29	The Immunology of Human Immunodeficiency Virus Infection. , 2015, , 1526-1540.e3.		3
30	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Science Translational Medicine, 2014, 6, 243ra88.	12.4	222
31	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . Journal of Virology, 2014, 88, 12669-12682.	3.4	248
32	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature, 2014, 514, 455-461.	27.8	702
33	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface. Nature, 2014, 515, 138-142.	27.8	400
34	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	14.3	332
35	Isolation of human monoclonal antibodies from peripheral blood B cells. Nature Protocols, 2013, 8, 1907-1915.	12.0	167
36	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213

MARK CONNORS

#	Article	IF	CITATIONS
37	Cytotoxic Capacity of SIV-Specific CD8+ T Cells against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques. PLoS Pathogens, 2013, 9, e1003195.	4.7	24
38	Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site. Journal of Virology, 2012, 86, 5844-5856.	3.4	75
39	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature, 2012, 491, 406-412.	27.8	753
40	Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Current Opinion in HIV and AIDS, 2011, 6, 169-173.	3.8	82
41	Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles. PLoS Pathogens, 2011, 7, e1002002.	4.7	34
42	Long-term Nonprogressive Disease Among Untreated HIV-Infected Individuals. JAMA - Journal of the American Medical Association, 2010, 304, 194.	7.4	116
43	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. Journal of Virology, 2010, 84, 1631-1636.	3.4	304
44	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. Science, 2010, 329, 856-861.	12.6	1,600
45	Comparisons of CD8 ⁺ T Cells Specific for Human Immunodeficiency Virus, Hepatitis C Virus, and Cytomegalovirus Reveal Differences in Frequency, Immunodominance, Phenotype, and Interleukin-2 Responsiveness. Journal of Virology, 2009, 83, 2728-2742.	3.4	42
46	Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. Journal of Virology, 2009, 83, 188-199.	3.4	297
47	Defective Human Immunodeficiency Virus-Specific CD8 ⁺ T-Cell Polyfunctionality, Proliferation, and Cytotoxicity Are Not Restored by Antiretroviral Therapy. Journal of Virology, 2009, 83, 11876-11889.	3.4	167
48	Lytic Granule Loading of CD8+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control. Immunity, 2008, 29, 1009-1021.	14.3	500
49	Human Immunodeficiency Virus Viremia Induces Plasmacytoid Dendritic Cell Activation In Vivo and Diminished Alpha Interferon Production In Vitro. Journal of Virology, 2008, 82, 3997-4006.	3.4	72
50	CD25+Regulatory T Cells Isolated from HIV-Infected Individuals Suppress The Cytolytic And Nonlytic Antiviral Activity of HIV-specific CD8+T Cells in Vitro. AIDS Research and Human Retroviruses, 2007, 23, 438-450.	1.1	120
51	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	21.4	691
52	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood, 2006, 107, 4781-4789.	1.4	1,681
53	Qualitative host factors associated with immunological control of HIV infection by CD8 T cells. Current Opinion in HIV and AIDS, 2006, 1, 28-33.	3.8	6
54	CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology, 2006, 44, 736-745.	7.3	68

Mark Connors

#	Article	IF	CITATIONS
55	Diminished Production of Monocyte Proinflammatory Cytokines during Human Immunodeficiency Virus Viremia Is Mediated by Type I Interferons. Journal of Virology, 2006, 80, 11486-11497.	3.4	63
56	HIVâ€l–Infected Patients with Envelopeâ€Specific Lymphoproliferation or Longâ€Term Nonprogression Lack Antibodies Suppressing Glycoprotein 120 Antigen Presentation. Journal of Infectious Diseases, 2004, 189, 852-861.	4.0	9
57	Advances in understanding immunologic control of HIV infection. Current HIV/AIDS Reports, 2004, 1, 12-17.	3.1	16
58	The Differential Ability of HLA B * 5701 + Long-Term Nonprogressors and Progressors To Restrict Human Immunodeficiency Virus Replication Is Not Caused by Loss of Recognition of Autologous Viral gag Sequences. Journal of Virology, 2003, 77, 6889-6898.	3.4	143
59	Diminished Proliferation of Human Immunodeficiency Virus-Specific CD4 + T Cells Is Associated with Diminished Interleukin-2 (IL-2) Production and Is Recovered by Exogenous IL-2. Journal of Virology, 2003, 77, 10900-10909.	3.4	171
60	Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood, 2003, 101, 2711-2720.	1.4	887
61	The role of CD4+ and CD8+ T cells in controlling HIV infection. Current Infectious Disease Reports, 2002, 4, 461-467.	3.0	29
62	HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002, 417, 95-98.	27.8	1,132
63	HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature Immunology, 2002, 3, 1061-1068.	14.5	909
64	Frequency and function of HIV-specific CD8+ T Cells. Immunology Letters, 2001, 79, 141-150.	2.5	64
65	Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors. Journal of Immunology, 2000, 165, 1082-1092.	0.8	248
66	Resistance to Replication of Human Immunodeficiency Virus Challenge in SCID-Hu Mice Engrafted with Peripheral Blood Mononuclear Cells of Nonprogressors Is Mediated by CD8+T Cells and Associated with a Proliferative Response to p24 Antigen. Journal of Virology, 2000, 74, 2023-2028.	3.4	35
67	HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Medicine, 1999, 5, 518-525.	30.7	712
68	Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques. Journal of Virology, 1998, 72, 164-169.	3.4	438
69	Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSV. Vaccine, 1992, 10, 475-484.	3.8	146